eTILÒ & eCARÒ Therapies: CRISPR/Cas9 Engineered T-Cells to Treat Solid Tumors
Time: 9:00 am
day: Post-Conference Solid Tumor Focus Day
Details:
- CRISPRomics discovery platform identified SOCS1 and Regnase-1 as top T-cell targets enhancing functionality
- Inactivation of SOCS1 and Regnase-1 enhances the activity of CRISPR/Cas9-engineered TIL (eTILÒ) against solid tumors
- Inactivation of SOCS1 and Regnase-1 enhances the activity of CRISPR/Cas9-engineered CARTs (eCARÒ) against solid tumors
